Tandem Therapeutics AG

The core activity of Tandem Therapeutics AG is the development of transformative medicines that focus on the extracellular matrix, particularly for the treatment of fibrotic diseases and fibrotic cancer forms. The company uses Matrix-Targeting-Peptides (MTP) that conditionally target disease-associated matrix changes to overcome the extracellular matrix barrier and enable new therapeutic approaches.